Other investigators have found that the anti-tumor effects of small molecule-based PP2A activators, when tested in models of MYC-driven cancers such as Burkitt lymphoma, KRAS-driven non–small cell lung cancer, or triple-negative breast cancer, were related to the ability of PP2A to decrease the MYC oncogene on the transcriptional and protein stability levels [12]. This evidence concerns the gene KRAS and neoplasm.